Researcher to test new treatment for deadliest form of brain cancer
A major clinical trial will investigate whether a combination of two drugs can help patients with brain cancer live longer. Clinical Associate Professor Anders Rosendal Korshøj has received an LF Fellowship of DKK 11 million from the Lundbeck Foundation for the project.
Up to 300 people in Denmark are affected each year by the most common and deadliest form of brain cancer, glioblastoma. Patients undergo surgery, radiotherapy and chemotherapy, but these treatments come at the expense of quality of life, and sooner or later the patients relapse and die from the disease.
Anders Rosendal Korshøj, Clinical Associate Professor at the Department of Clinical Medicine and Consultant in the Department of Neurosurgery at Aarhus University Hospital, will therefore test two drugs which, in combination, have the potential to prolong patients’ lives.
‘The aim is to give patients a significantly longer life without compromising their quality of life,’ says Anders Rosendal Korshøj.
The LF Fellowship grant from the Lundbeck Foundation will enable him to launch the project, which has been in development for two to three years. The ambition is for patients at hospitals throughout Denmark who have recently been diagnosed with glioblastoma to be offered the opportunity to participate in the trial.
The two drugs are intended to target different mechanisms in the disease: signals from normal brain cells that cause cancer cells to grow, and the networks through which the cancer cells communicate. According to Anders Rosendal Korshøj, targeting these two different mechanisms simultaneously offers a greater chance of slowing the progression of the disease.
This article is based on press material from the Lundbeck Foundation.
Contact
Consultant and Clinical Associate Professor Anders Rosendal Korshøj
Aarhus University, Department of Clinical Medicine, and
Aarhus University Hospital, Department of Neurosurgery
Email: [email protected]